This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

AOP: 313


A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
Skin disease by stimulation of TLR7/8
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.0

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool


The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

Hiroyuki Komatsu (1) Takao Ashikaga (1) Tomoki Fukuyama (1) Ken Goto (1) Shinko Hata (1) Shigeru Hisada (1) Shiho Ito (1) Sumie Konishi (1) Tadashi Kosaka (1) Kiyoshi Kushima (1) Shogo Matsumura (1) Takumi Ohishi (1) Yasuharu Otsubo (1) Junichiro Sugimoto (1) Yasuhiro Yoshida (1)

(1) AOP Working Group, Testing Methodology Committee, The Japanese Society of Immunotoxicology

Corresponding author:  Komatsu (

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
Evgeniia Kazymova   (email point of contact)


Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Takumi Ohishi
  • Hiroyuki Komatsu
  • Evgeniia Kazymova


This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help
  • Julija Filipovska

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
1.75 Under Development
This AOP was last modified on May 26, 2024 20:39

Revision dates for related pages

Page Revision Date/Time
Stimulation, TLR7/8 November 21, 2020 07:14
Increase, IL-23 from matured dendritic cells November 23, 2020 06:44
Th17 cell migration and inflammation induction November 23, 2020 06:59
Psoriatic skin disease November 23, 2020 07:04
Maturation of TNF/iNOS-Producing Dendritic Cells November 23, 2020 06:38
Stimulation of TLR7/8 leads to Increase of IL-23 December 27, 2019 05:33
Increase of IL-23 leads to Th17 cell migration and inflammation induction December 27, 2019 05:35
Th17 cell migration and inflammation induction leads to Skin disease December 27, 2019 05:41
Imiquimod December 27, 2019 04:57
Resiquimod December 27, 2019 04:58


A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

Toll-like receptor (TLR) 7 and TLR8 are pattern recognition receptors that are known to activate antiviral reaction of immune system, hyperactivation of which can lead to psoriatic skin disease when hyperactivation of them occurred. The relationship between TLR7/8 and immune functions is well understood, and antiviral compound that work by stimulating TLR7/8 have been developed. TLR7/8 agonists such as imidazoquinolin compounds stimulate these TLRs through the formation of homodimer. This signal activates the IL-23/IL-17 axis, which leads to  psoriasis and other related skin diseases.

Activation of the IL-23 / IL-17 axis and causes abnormal proliferation and inflammation of the epidermis, which is a pathological condition of psoriasis. This AOP shows an association between TLR7 / 8 stimulation and psoriatic skin disease.

TLR7-mediated signaling in plasmacytoid dendric cells (pDC) is mediated in a MyD88-dependent fashion, which initiates an IRF7, IRAK1, TRAF6, TRAF3, and IKKα-mediated response, secreting vast amounts of IFN type 1. Similarly, upon engagement of ligands in endosomes, TLR8 initiate the MyD88-dependent pathway culminating in synthesis and release of proinflammatory mediators, such as TNF-α via NF-κB activation. IFN-α and TNF-α cooperatively mature myeloid dendritic cells. TLR7/8 agonist stimulates a specific population of inflammatory dermal dendritic cells referred as TNF and inducible nitric oxide synthase–expressing DCs (Tip-DCs) to produce IL-23 after maturation by enhanced transcriptional activity.

IL-23R is mainly expressed in Th17 cells. In chronic psoriasis, the cytokines IL-12 and IL-23 produced by resident DC are the main causes. Not only does the expression of IL-23 increases in the skin tissue of the lesion, Th17 cells also increase.

Mature Th17 cells are activated by IL-23 stimulation. Signaling through IL-23 produces cytokines  IL-17 and IL-22 that mediate the psoriasis response and promote neutrophil migration into the epidermis, epidermal cell proliferation, and similar responses, which lead to the development of a psoriasis rash. In mice, psoriasis-like hyperplasia is induced by the application of IL-23 but does not occur in IL-17A and IL-22 KO mice, so IL-17A and IL-22 play an important role downstream of IL-23.

IL-17 receptor form heterodimers, and IL-17RA / IL-17RC appears in a variety of cells, including fibroblasts and epidermal cells. IL-17RE / IL-17RA expressed in epidermal cells and IL-17C binding  are also important in the pathology of psoriasis. Immunohistochemically, IL-17A is expressed only in cells of the dermal papilla layer, while IL-17C is widely expressed in cells such as hyperproliferative overexpressed keratinocytes, leukocytes, and vascular endothelial cells. IL-17C produces keratinocytes by bacterial stimulation and further stimulates keratinocytes to induce the production of various cytokines and chemokines. Keratinocytes are known to be self-activated by IL-17C.

IL-17 and IL-22 secreted from Th17 act on keratinocytes, causing abnormalities in keratinocytes through the secretion of inflammatory cytokines, chemokines, growth factors, and antimicrobial peptides, and thereby exacerbating  the skin symptoms of psoriasis.

The creation of this AOP began with an examination of important event relationships brought about by TLR7 / 8 activity due to environmental or genetic factors and resulting in abnormal differentiation of keratinocytes, which leads to thickening of the epidermis and its resultant autoimmune skin disease, psoriasis

AOP Development Strategy


Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Psoriasis is an chronic autoimmune disease characterized  by chronic epithelial inflammatory disease induced by environmental factors such as infection, stress, smoking or alcohol consumption as well as by genetic factors. The onset of psoriasis has been reported to be triggered by drugs and chemical substances use, including  beta-blockers, chloroquine, lithium, ACE inhibitors, indomethacin, terbinafine, and interferon alpha. Diagnosis is based on the type and distribution of the lesions.

Psoriasis occurs when abnormal differentiation (keratosis) of keratinocytes leads to thickening of the epidermis. Patients often exhibit an erythema with a clear border and epidermal hyperplasia, stratum corneum hyperplasia, heterocytosis in the stratum corneum, mixed skin moist cells of neutrophilic granulocytes and T cells in the epidermis. Dendritic cells (DC) and macrophages are associated with silver-white plaque. Neutrophilic effusion (Munro microabscesses) are observed in the epidermis, and CD8+ T cells (Tc17) increase the expression of angiogenesis related genes.

The main therapeutic agents are mild topical treatments such as emollients, salicylic acid, coal tar preparations, anthralin, corticosteroids, vitamin D3 derivatives, retinoids, calcineurin inhibitors or tazarotene. UV therapy is also used for moderate or severe psoriasis. Widespread psoriasis is treated with systemic therapies such as immunomodulators methotrexate, cyclosporin, retinoids and other immunosuppressants used alone or in combination.

Although there are stressors that are well known to induce psoriasis-like skin inflammation in mice, this AOP is based primarily on an understanding of stimulation caused by imiquimod, resiquimod or LL37-selfRNA complexes, for which a significant body of scientific literature has been published.

As a test model for psoriasis, an Autoimmune skin disease, mouse tests that induce skin inflammation like psoriasis are frequently conducted using the imidazoquinoline derivative imiquimod. This AOP is primarily based on an understanding of stimuli caused by imiquimod, resiquimod, or LL37-selfRNA complexes.

Imiquimod is derived from imidazoquinoline and is often used to create mouse models. It is our hope that this AOP will contribute to greater knowledge about the development of psoriatic skin diseases that start from stimulation of TLR as well as the development of new treatment targets for psoriasis.


Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help


Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 1706 Stimulation, TLR7/8 Stimulation of TLR7/8
KE 1822 Maturation of TNF/iNOS-Producing Dendritic Cells Maturation, TNF/iNOS-Producing Dendritic Cells
KE 1707 Increase, IL-23 from matured dendritic cells Increase of IL-23
KE 1708 Th17 cell migration and inflammation induction Th17 cell migration and inflammation induction
AO 1709 Psoriatic skin disease Skin disease

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
All life stages Not Specified

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
Homo sapiens Homo sapiens High NCBI
Mus musculus Mus musculus Moderate NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Mixed High

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

TLR7/8 is stimulated when imidazoquinolin compounds or stimilar  agonists from  homodimers TLR7-mediated signaling in plasmacytoid dendritic cells (pDC) is mediated in a MyD88-dependent fashion, which initiates an IRF7, IRAK1, TRAF6, TRAF3, and IKKα-mediated response,thereby secreting large amounts of IFN-α. Similarly, the engagement of ligands in endosomescauses TLR8 initiate the MyD88-dependent pathway, culminating in synthesis and release of TNF-a and other proinflammatory mediators, via NF-κB activation.

IFN-α and TNF-α cooperatively mature myeloid dendritic cells. TLR7/8 agonist stimulates a  specific population of inflammatory dermal dendritic cells referred as Tip-DCs to produce IL-23 after maturation by enhanced transcriptional activity.

Naive T cells differentiate into Naive Th17 by both IL-6 and TGF-β cells that express the transcription factors ROR-γt, ROR-α, and STAT3. These naive Th17 cells are self-activated by IL-21 in an autocrine manner and mature into Th17 cells which express IL-23 receptor on cell surface. Mature Th17 cells are activated by IL-23 stimulation. IL-23-mediated signal transduction produces cytokines IL-17.

IL-17 mediates the psoriasis response, promoting such activities as neutrophil migration to the epidermis,and proliferation of epidermal cells, which leads to the outbreak of psoriasis rash. Thus, psoriatic skin is induced mainly by overproduction of IL-17, which leads to a variety of  adverse effects. We have identified a number of key events (KEs) along this pathway and created an AOP for stimulation of TLR7/8 that leads to psoriatic skin disease based on these key event relationships(KERs).

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

The proposed AOP for psoriasis-like skin thickening resulting from abnormal differentiation of keratinocytes, starting with Toll-like receptor (TLR) 7/8 activity, is independent of life stage, gender, or age (Lowes et al. 2007). The pathogenesis of psoriasis, an autoimmune disease, is genetically predisposed (3), but the autoantigen that causes psoriasis has not been identified (Zaba et al. 2008). Other causes of psoriasis are caused by external and internal triggers such as mild trauma, sunburn, infection, systemic drugs, and stress (Hansel et al. 2011). Stimulation of TLR7 / 8 releases INF-α and TNF-α in large amounts to produce IL-23, and Th17 cells mature by the stimulation to produce IL-17 and IL-22. In psoriasis skin formation, cytokines such as TNF-α, IL-23, and IL-17 work continuously. Since TNF-α inhibitors significantly suppressed IL-17A and IL-23p19 expression in psoriatic eruptions (Leonardi et al. 2012), by suppressing self-activation of Tip-DC by TNF-α, It can be seen that IL-23 and IL-17A production was suppressed. Anti-IL-17 and anti-IL-17RA antibodies suppress IL-17A and IL-17C, which are highly expressed in psoriatic eruptions. In particular, anti-IL-17RA antibody has been shown to normalize the expression of keratinocyte-related genes and IL-17C production two weeks after administration, followed by normalization of IL-17A production from leukocytes.

In mice, subcutaneous administration of IL-23 induced psoriatic eruption and IL-17A expression (K. A. et al. 2013), and IL-17C transgenic mice overexpressing IL-17C in keratinocytes showed psoriatic eruption. As shown in (8), the reaction of psoriasis-like eruption occurs in mice due to the chain of stimulation to T cells and epidermal cells starting from TLR.

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

Stressor, MIE and later events:MyD88 knock out(KO) mice

TLR7 (TLR7 / 8 in human) recognizes the imidazoquinoline derivative, binds to the adapter molecule MyD88, activates IRAKs (IL-1 receptor associated kinases), interacts with TRAF6 (TNF receptor associated factor 6) and IKK (Activates the IκB kinase complex). It phosphorylates IκB, induces its degradation, and transfers the transcription factor NF-κB to the nucleus. This pathway is called MyD88-dependent pathway and is essential for the production of inflammatory cytokines such as TNF-α (Akira S, Takeda K .: Nat Rev Immunol. Jul; 4: 499-511, 2004). When pDC is stimulated with a TLR7 / 8 ligand, the transcription factor IRF7 constitutively expressing pDC and MyD88 associate directly. IRF7 activity does not occur when pDCs of MyD88 KO mice are stimulated with TLR7 / 8 ligand. IRF7 is also activated by binding to TRAF6, leading to IFN-α production, which requires the Myd88 / TRAF6 / IRF7 complex. (Satoshi U, Shizuo A: Virus 54; 2: 145-152,2004)

Imiquimod 5% cream was applied to the left flank of female SKH-1 hairless mice (25 g body weight). The IFN-α and TNF-α concentrations in the skin after 1 and 2 hours of application increased these concentrations compared to the untreated skin.

In C57BL / 6 mice (8-12 weeks old) sensitized with 0.5% dinitrofluorobenzene (DNFB) as an antigen, imiquimod 5% cream was applied to the auricle once a day for 3 days. The application of imiquimod 5% cream promoted edema of the ears of mice (promoted DTH) compared to the base cream group. Imiquimod activates antigen-specific T cells by topical application to the skin. (Beserna Cream Interview Form Mochida Pharmaceutical Co., Ltd.)


KE-1 and later event:IL-17, IL-22 KO mice

In mice, psoriasis-like hyperplasia is induced by the application of IL-23, but this effect does not occur in IL-17A and IL-22 KO mice. IL-17A deficient mice show little epidermal hyperplasia after intradermal administration of IL-23. WT mice treated with anti-IL-17A Ab did not show IL-23-induced epidermal hyperplasia. IL-17 KO mice treated with IL-23 do not induce TNF-α mRNA and do not cause epidermal thickening. IL-22 did not increase in IL-17-/-mice after IL-23 administration, and IL-17 clearly increased in IL-22-/-mice. In IL-17-/-, IL-22-/-and WT mice treated with IL-23, immunohistochemically CD3 + T cells, CD11c (dendritic cells), F4 / 80 (macrophages), Gr-1 (Neutrophils) were analyzed. There was no difference in F4 / 80 and Gr-1 + cells in IL-17A-/-compared to WT mice, and CD3 + T cells decreased, but there was no obvious difference in IL-22-/-mice .

These data suggest that cytokines alone are not sufficient to mediate IL-23-induced epidermal changes, and that IL-17 and IL-22 are downstream mediators of mouse skin IL-23-induced changes. Therefore, Th17 cytokines are required for the generation of IL-23-mediated skin lesions.

KE-2 and later events: Mouse psoriasis-like dermatitis model

When TPA (12-O-tetradecanoy1phorbol-13-acetate) on the dorsal skin of K14 / mIL-1F6 gene-modified mice overexpress mouse IL-1F6 (IL-36a) selectively under the keratin 14 promoter was applied, skin pathological findings specific to psoriasis were observed, such as epidermal hyperplasia, epidermal exfoliation and micro-abscess formation, and wet inflammatory cells in the dermis. Quantitative RT-PCR measures mRNA expression levels of inflammatory chemokines and cytokines in skin tissues, and includes inflammatory chemokines: CCL3, CCL4, CXCL10, CXCL1, and cytokines: IL-23, IL-12, IL-1β, etc. These expressions were elevated. (Kyowa Hakko Kirin Co., Ltd.)

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help


List of the literature that was cited for this AOP. More help